Answers are grounded in this paper and cite their sources.
Key Points A tetravalent BsAb against CD33 treated AML human xenografts despite CD33 internalization. BsAb with bivalent versus monolavent binding to CD33 and CD3 had more than 10-fold greater potency against leukemia.
No takes yet. Share an insight, caveat, or question.
Hoseini et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: